PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation

Completed · Phase 2

Conditions studied: Glioblastoma Multiforme

In brief

To obtain preliminary data in a randomized phase II study whether PPX/RT improves progression-free survival as compared to temozolomide/RT for patients with GBM without MGMT methylation.

Key facts

Study ID

NCT01402063

Run by

Brown University

People needed

63

Starts

2011-09-01

Expected to finish

2015-06-01

Last updated by the study team

2020-02-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically proven diagnosis of glioblastoma or gliosarcoma (WHO grade IV)
• GBM must have unmethylated MGMT as determined by central laboratory
• Diagnosis of GBM must be made by biopsy or surgical excision, either partial or complete; as long as there is sufficient tissue to determine MGMT status
• No prior chemotherapy or radiation for brain tumor
• Must be able to tolerate brain MRIs.
• A diagnostic contrast-enhanced MRI must be performed postoperatively within 42 days prior to study registration.
• KPS >60.
• Age > 18
• Life expectancy of at least 3 months.
• Absolute neutrophil count > 1500/mm3, Platelets > 100,000/mm,
• Creatinine < 2 x ULN
• ALT or AST < 3 x upper limit of normal (ULN) and total bilirubin < 1.5x ULN.
• Patients with a prior history of low grade glioma who did not receive prior radiation or chemotherapy with transformation to grade IV brain tumor are eligible.
• Women must be non-lactating, and surgically sterile, post-menopausal or have a negative serum pregnancy test and agree to use adequate birth control. Males must agree to use adequate birth control.
• Voluntary, signed informed consent.

You may not qualify if…

• Acute infection or other medical condition that would impair study treatment
• No other active invasive malignancy unless disease free for at least 3 years.
• Prior temozolomide or PPX.
• Prior use of Gliadel wafers or any other intratumoral or intracavitary treatment are not permitted.
• Prior radiotherapy to the head or neck (except for T1 glottic cancer), resulting in overlap of radiation fields.
• No diffuse leptomeningeal disease, or gliomatosis cerebri.
• Use of any other experimental chemotherapy drug within the 60 days prior to randomization and during the trial. (Use of a non-chemotherapy investigational agent must be approved by the Brown University Oncology Group)

Where it is running

• UCSD Cancer Center — La Jolla, California, United States
• Maine Medical Center — Scarborough, Maine, United States
• UMASS Medical Center Cancer Center — Worcester, Massachusetts, United States
• SUNY Medical Center — Syracuse, New York, United States
• PSU — Hershey, Pennsylvania, United States
• Thomas Jefferson University Cancer Center — Philadelphia, Pennsylvania, United States
• Rhode Island Hospital — Providence, Rhode Island, United States
• UT Southwestern Cancer Center — Dallas, Texas, United States
• University of Washington — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.